New book by Larry Connors Click here Improve your trading - See how
CyDex Pharmaceuticals, Inc. today announced the presentation of Phase 2 clinical trial results of its novel, proprietary Captisol-Enabled(R) budesonide/azelastine nasal spray (CDX-313) for seasonal allergic rhinitis (SAR). The budesonide/azelastine combination nasal spray demonstrated statistically significant improved results over a nasal spray placebo.
A randomized, double-blind, placebo-controlled, three-way cross-over study was conducted in 108 SAR patients to compare the relative efficacy of Captisol-Enabled Budesonide + Azelastine Nasal Spray (Single Solution) and Rhinocort Aqua(R)/ (Suspension) + Astelin(R) Nasal Spray (Solution) against a placebo nasal spray solution in the treatment of allergic rhinitis in an environmental exposure chamber.
Relief of all nasal symptoms as measured by the Total Nasal Symptom Score (TNSS) was significantly greater than placebo from 20 minutes following administration until the session end (10 hours) for both Captisol-Enabled budesonide/azelastine and Rhinocort Aqua/Astelin (p<0.0001). Onset of action of relief from itchy nose and sneezing were significantly faster at 10 minutes for Captisol-Enabled budesonide/azelastine compared to Rhinocort Aqua/Astelin.
Relief of all eye symptoms as measured by the Total Ocular Symptom Score (TOSS) was significantly greater than placebo from 40 minutes following administration until the session end (10 hours) for both Captisol-Enabled budesonide/azelastine and Rhinocort Aqua/Astelin (p<0.0001). Captisol-Enabled budesonide/azelastine provided the same or greater numerical TOSS relief than Rhinocort Aqua/Astelin and longer-lasting relief of red/burning eyes and itchy eyes.
Theron Odlaug, Ph.D., President and CEO of CyDex, commented, "Our ongoing research and development progress at CyDex, as demonstrated by this Phase 2 clinical trial, will continue to propel us forward as we grow to become a formidable specialty pharmaceutical company. The Captisol-Enabled budesonide/azelastine nasal spray product is one we intend to license to a commercial partner. Our ongoing strategy involves development of products to license as well as products we intend to retain, develop and commercialize within CyDex Pharmaceuticals."
About Captisol-Enabled Budesonide/Azelastine Nasal Spray
Captisol-Enabled Budesonide/Azelastine Nasal Spray is being studied as a novel combination of two drugs used to treat seasonal allergic rhinitis: budesonide and azelastine. Budesonide has been used clinically for more than 20 years. Azelastine is an antihistamine currently marketed as Astelin(R) nasal spray. Captisol(R), CyDex's patented sulfobutyl ether B-cyclodextrin, enables the combination of the two drugs in an aqueous solution. CyDex has previously shown that Captisol-Enabled Budesonide provided more non-nasal symptom relief than the currently marketed product. The safety data generated to date has shown Captisol-Enabled Budesonide/Azelastine Nasal Spray to be well tolerated with no significant adverse events. CyDex is planning a Phase 3 clinical trial with a development and commercialization partner.
About CyDex Pharmaceuticals
CyDex Pharmaceuticals, Inc. is a specialty pharmaceutical company developing products and licensing its Captisol(R) technology. CyDex is developing its own pipeline of products using its enabling technology solutions and partnering with leading pharmaceutical, specialty pharmaceutical and biotechnology companies. The company maintains patents in the U.S. and worldwide for its Captisol and cyclodextrin technologies, and a comprehensive FDA drug master file for client use. For additional information on business development opportunities, please contact Ralph Johnston at rjohnston@cydexpharma.com or 913.685.8850. CyDex is a privately held company located in suburban Kansas City. To learn more about the company, please visit www.cydexpharma.com.
Rhinocort Aqua is a registered trademark of AstraZeneca.
Astelin is a registered trademark of Meda Pharmaceuticals.
SOURCE: CyDex Pharmaceuticals, Inc.
CyDex Pharmaceuticals, Inc. Allen K. Roberson, 913-685-8850 Chief Financial Officer aroberson@cydexpharma.com
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
